ConexiantAAO Updates HCQ Retinopathy Guidance

✅ Guideline Update

The AAO revised HCQ retinopathy screening guidance, synthesizing retinal imaging and AI analysis advances. The update focuses on long-term users, a predominantly female population treated for systemic lupus erythematosus and rheumatoid arthritis.

Clinical Considerations

• Risk of toxicity was less than 1% within 5 years and less than 2% within 10 years at doses of no more than 5 mg/kg/day of real body weight.
• Annual risk remained below 5% even after 20 years of therapy among patients without prior toxicity, though risk increased with higher daily doses and longer duration.
• Risk may be doubled in patients with renal disease due to increased circulating drug levels, with elevated risk also seen in tamoxifen users and those starting HCQ at older ages.
• Toxicity does not develop continuously: the retina can remain stable for years before early structural changes emerge, and advanced disease may continue to worsen even after drug discontinuation.

Practice Applications

• Monitor cumulative dose against the 5 mg/kg/day real body weight threshold.
• Integrate OCT and FAF as primary screening modalities, with visual-field testing and multifocal ERG as confirmatory.
• Consider baseline screening near treatment initiation to establish a reference point.
• Recognize that annual screening may be deferred up to 5 years in patients without major risk factors.
• Interpret AI-based imaging analysis cautiously as it is not yet fully validated for routine clinical use.